Integra LifeSciences Holdings Co. (NASDAQ:IART) Short Interest Up 16.1% in October

Integra LifeSciences Holdings Co. (NASDAQ:IART) was the recipient of a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,110,000 shares, an increase of 16.1% from the September 30th total of 4,400,000 shares. Currently, 7.9% of the shares of the company are short sold. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is currently 4.6 days.

Analysts Set New Price Targets

A number of research firms recently commented on IART. Citigroup reduced their price objective on Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating for the company in a research report on Tuesday, October 1st. Bank of America reduced their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Morgan Stanley raised their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. JMP Securities reduced their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a report on Tuesday, July 30th. Finally, BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and a consensus target price of $26.50.

Institutional Trading of Integra LifeSciences

Several institutional investors have recently made changes to their positions in IART. State of Michigan Retirement System boosted its stake in Integra LifeSciences by 2.5% in the 1st quarter. State of Michigan Retirement System now owns 16,690 shares of the life sciences company’s stock worth $592,000 after purchasing an additional 400 shares during the period. CWM LLC boosted its position in shares of Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 425 shares during the last quarter. Blue Trust Inc. grew its stake in Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 444 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in Integra LifeSciences by 1.1% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 49,762 shares of the life sciences company’s stock valued at $1,764,000 after acquiring an additional 551 shares during the last quarter. Finally, Texas Permanent School Fund Corp lifted its stake in Integra LifeSciences by 1.5% in the 1st quarter. Texas Permanent School Fund Corp now owns 59,524 shares of the life sciences company’s stock worth $2,110,000 after purchasing an additional 870 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART opened at $19.48 on Thursday. The firm’s 50 day simple moving average is $18.69 and its two-hundred day simple moving average is $24.70. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. The company has a market capitalization of $1.51 billion, a P/E ratio of 67.17, a P/E/G ratio of 0.65 and a beta of 1.09. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $45.42.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Monday, July 29th. The life sciences company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.01. The company had revenue of $418.20 million during the quarter, compared to the consensus estimate of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. Integra LifeSciences’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.71 EPS. Research analysts expect that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.